Additionally, we identified several genes involved in the response to TMZ and constructed a signature comprising six genes, MROH8, BET1, PTPRN2, STC1, NKX3-1, and ARMC10, which are promising therapeutic targets for TMZ-resistant GBM. This evidence concerns the gene BET1 and glioblastoma.